NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Coupang, Inc. ("Coupang, Inc." or the "Company") (NYSE: CPNG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Coupang, Inc. investors who were adversely affected by alleged securities fraud between May 7, 2025 and December 16, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/coupang-inc-lawsuit-su ...

Core Viewpoint - An investigation has been initiated by Levi & Korsinsky into Gartner, Inc. regarding potential violations of federal securities laws, particularly focusing on the company's financial disclosures and earnings guidance [1][2]. Financial Performance and Disclosures - Gartner's fourth quarter earnings release on February 3, 2026, highlighted an earnings-per-share (EPS) beat against analyst estimates, but simultaneously revealed that revenue fell short of consensus expectations [2]. - The company provided a full-year 2026 outlook indicating a year-over-year decline, raising concerns about the transparency of its financial metrics [2]. - Gartner had previously guided investors to expect adjusted EPS of at least $12.65 for 2025, based on 78 million shares and anticipated stock repurchases to offset dilution [2]. - The company repurchased over $1 billion of stock during Q3 2025, resulting in a 6% reduction in share count year-over-year [2]. Market Reaction - Following the earnings release, Gartner's shares experienced a decline of more than 20%, reaching a new 52-week low below $160, with trading volume significantly exceeding normal levels [2].

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 27, 2025, to November 11, 2025, seeking damages for misleading statements regarding the company's financial health and operations [1]. Group 1: Lawsuit Details - The class action was filed in the United States District Court for the Central District of California, seeking to recover damages for all persons and entities that purchased Beyond Meat securities during the specified Class Period [1]. - Investors have until March 24, 2026, to request appointment as Lead Plaintiff for the class [1]. Group 2: Company Background - Beyond Meat operates in the food industry, focusing on developing, manufacturing, marketing, and selling plant-based meat products under the "Beyond" brand in the U.S. and internationally [1]. - The company has been facing challenges such as shrinking demand, increasing debt, and losses, with a primary goal of achieving positive EBITDA by the end of 2026 [1]. Group 3: Allegations and Financial Impact - The complaint alleges that Defendants made materially false and misleading statements about the company's business and operations, failing to disclose significant asset impairment charges that were likely to occur [1]. - On October 24, 2025, Beyond Meat reported an expected non-cash impairment charge for Q3 2025, leading to a stock price drop of 23.06% [1]. - Subsequent announcements regarding delays in financial reporting and actual impairment charges resulted in further declines in stock price, with a reported loss from operations of $112.3 million for Q3 2025, including $77.4 million in non-cash impairment charges [1].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [1] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [1] Allegations and Misstatements - Defendants allegedly made materially false and misleading statements regarding Inovio's business and prospects, including: - Deficiencies in the manufacturing of the CELLECTRA device [1] - Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1] - Insufficient information to justify eligibility for FDA accelerated approval or priority review [1] - Overstated regulatory and commercial prospects for INO-3107 [1] Stock Price Impact - Following the revelation of a manufacturing issue on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [1] - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [1]

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. ("Quantum" or the "Company") (NASDAQ: QNTM). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, ...

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation and certain officers for alleged violations of federal securities laws during the Class Period from July 25, 2025, to August 14, 2025, seeking damages for investors who purchased SLM securities during this time [1] Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey, under docket number 25-cv-18834, representing all persons and entities, excluding defendants, who invested in SLM securities during the specified Class Period [1] - Investors have until February 17, 2026, to request appointment as Lead Plaintiff for the class [1] Group 2: Company Overview - SLM Corporation, commonly known as Sallie Mae, primarily originates and services private education loans (PELs) to students and their families, emphasizing its "high-quality" PELs and loss mitigation programs [1] - The company classifies PELs as in repayment when borrowers are making interest-only or fixed payments, or have entered full principal and interest repayment status after any applicable grace period [1] Group 3: Financial Metrics and Concerns - Delinquency rates on SLM's PELs are a critical metric for investors assessing the health and profitability of the business [1] - Defendants allegedly misled investors by attributing rising delinquency rates to "normal seasonal trends" and minor refinements in loan offerings, while failing to disclose significant increases in early-stage delinquencies [1] Group 4: Impact of Findings - On August 14, 2025, TD Cowen reported a 49 basis point month-over-month increase in July 2025 delinquencies, contradicting prior reassurances from SLM's executives [1] - Following the TD Cowen report, SLM's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 per share on August 15, 2025 [1]

Core Viewpoint - An investigation has been announced regarding Inovio Pharmaceuticals, Inc. for potential violations of federal securities laws affecting investors [1] Group 1 - The Law Offices of Howard G. Smith are representing investors who may have suffered losses in Inovio Pharmaceuticals, Inc. [1] - Investors are encouraged to contact the law firm to discuss potential claims for recovering losses [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Bath & Body Works, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the class period from June 4, 2024, to November 19, 2025 [1][7]. Group 1: Allegations - The lawsuit claims that Bath & Body Works' strategy of pursuing "adjacencies, collaborations and promotions" did not effectively grow the customer base or deliver the expected growth in net sales [2]. - It is alleged that the company relied on brand collaborations to mask weak underlying financial results as its growth strategy faltered [2]. - The complaint asserts that Bath & Body Works is unlikely to meet its previously issued financial guidance due to these issues, rendering the defendants' positive statements materially misleading [2]. Group 2: Legal Process - Investors affected by the alleged fraud can seek to be appointed as lead plaintiffs by March 16, 2026, through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff represents the interests of all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [4]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and investor protection, representing both individual and institutional investors [6][8].

Group 1 - The article discusses a class action lawsuit against Charming Medical Limited (MCTA) for securities fraud, with a deadline for shareholders to file a lead plaintiff motion by February 17, 2026 [1] - The lawsuit claims that during the class period from October 10, 2025, to November 12, 2025, the company made materially false and misleading statements regarding its business and operations [1] - The SEC halted trading of Charming securities on November 11, 2025, due to potential manipulation through social media recommendations aimed at artificially inflating the stock price [1] Group 2 - Allegations in the lawsuit include that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company failed to disclose material adverse facts [1] - The complaint asserts that the company's public statements omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] - Shareholders who acquired Charming securities during the class period are encouraged to participate in the lawsuit to recover losses under federal securities laws [1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the efficacy and regulatory approval timeline of its gene therapy AMT-130 for Huntington's disease [1][2] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease [1] - The leading drug candidate, AMT-130, aims to slow the progression of Huntington's disease, a fatal genetic disorder with no current cure [1] Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130 in March 2022 [1] - The FDA had previously agreed that the Pivotal Study results could be compared to an external historical dataset (Enroll-HD) instead of using a placebo comparator [1] - The company claimed that the results indicated a significant reduction in neurodegeneration, leading to expectations of accelerated approval from the FDA [1] Stock Performance and Fundraising - Following the announcement of positive topline results on September 24, 2025, uniQure's stock price surged nearly 250%, from $13.66 to $47.50 per share [1] - The company subsequently raised approximately $345 million through a public offering of over 5.7 million shares, despite uncertainties regarding AMT-130's approval timeline [2] Disclosure of Material Information - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would support a BLA submission, leading to a stock price drop of over 49% [2] - The lawsuit alleges that uniQure misrepresented the approval status of the Pivotal Study and downplayed the likelihood of delays in the BLA submission process [2]